Professor Jean-François Korobelnik joins us to discuss aflibercept and its effectiveness as a widely used and well-tolerated anti-vascular endothelial growth factor (VEGF) inhibitor. He also briefly describes the APOLLON study, looking at the real-life treatment, monitoring and outcomes of treatment in patients with diabetic macular edema in routine clinical practice.
Questions:
1. What advantages does aflibercept offer compared with other anti-vascular endothelial growth factor (VEGF) therapies in diabetic macular edema (DME)? (0:11)
2. Could you tell us a little about the design of the APOLLON study? (0:34)
3. How do injection frequencies in real-world studies differ from those in randomised clinical trials? (1:20)
4. What have been the six-month findings of this study? (2:08)
5. What are the clinical implications of these findings and what future studies are planned? (2:52)
Speaker disclosures: Jean-François Korobelnik has nothing to disclose in relation to this interview.
Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.
